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Abstract
Chemoresistance of lung cancer cells is a key factor that limits the treatment of lung cancer
patients. Patients may initially respond to standard chemotherapy, but this is often followed
by rapid development of drug resistance and disease progression. Tumor heterogeneity and
the presence of putative cancer stem-like cells (CS-LCs) provide a viable explanation for the
chemoresistance of several types of tumors. In this book chapter, we will first describe the
current knowledge of the role of both tumor heterogeneity and CS-LCs in lung cancer che-
moresistance, tumor progression and metastasis. Next, we will discuss ongoing strategies at
the in vitro level to screen for more effective anticancer drugs. We will specifically focus in
three-dimensional (3D) culture systems (Spheroids and tumorspheres) and their application
in anticancer drug discovery for lung cancer.
Keywords: chemoresistance, tumor heterogeneity, cancer stem cells, spheroids
tumorspheres, 3D systems
1. Introduction
Lung cancer is the leading cause of cancer death among men and the second leading cause of
cancer death among women worldwide [1]. Despite important advances in our knowledge of
cancer cell biology and anti-cancer therapies such as chemotherapy, radiotherapy and targeted
therapies, the five-year survival rates remain poor (<15%). Lung tumors are broadly classified
into small cell lung cancer (SCLC) and non-small lung cancer (NSCLC). SCLCs are defined by
neuroendocrine differentiation and small cell morphology of the tumor cells and account for
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15–20% of newly diagnosed lung malignancies. Interestingly, SCLC tumors tend to recur as
chemoresistant variants and occasionally show progression to a NSCLC phenotype [2]. Regar-
dless of the type, chemoresistance appears in most lung tumors, presenting a challenge to the
development of new therapeutic regimes. The failure of the management of lung cancer is
largely attributed to the inherent and/or acquired resistance that limits the efficacy of current
therapies. Several characteristics of lung tumors have been identified for long time as key
driving factors that lead to increased chemoresistance. Among them, mutations, amplifications
and overexpression of multidrug-resistant proteins have been investigated in vitro using cell
lines growing as adherent monolayers (2D systems). Intratumoral heterogeneity was also
recognized long time ago as a key factor contributing to chemoresistance and soon tumor
spheroids were developed with the aim to replicate in vitro “mini-tumor” with more complex
and heterogeneous 3D architecture mimicking primary tumors. These tumor spheroids were
routinely obtained by culturing cancer cells in serum-containing media under anchorage-
independent conditions. The isolation of putative cancer stem cells from solid tumors was
done by culturing cancer cells under anchorage-independent condition but in serum-free
media (initially with few supplements). Under these conditions, cancer cells grow as “floating
tumorspheres” and form complex 3D structures similar to spheroids. It is widely accepted that
“floating tumorspheres” are enriched with cancer stem-like cells that are inherently chemor-
esistant. For clarity and consistency, we will call “spheroids” and “tumorspheres” to masses of
cancer cells growing as floating spheres in serum-containing and serum-free media, respec-
tively. The aim of this chapter is to (1) briefly describe the main factors—relevant to 3D in vitro
models contributing to chemoresistance (intratumoral heterogeneity and the presence of CS-
LCs) and (2) discuss the application of spheroids and tumorspheres as tools for screening
anticancer drugs targeting chemoresistant cancer cells.
1.1. Intratumoral heterogeneity
Intratumoral heterogeneity is a term that refers to the presence of cells within a tumor with
varying degrees of morphology, proliferation rate, ability to metastasize, sensitivity to drugs,
dependence on growth signals and tumor initiation/repopulation capacity. It has long been
recognized as a salient feature of most cancers and largely associated with tumor relapse. Both
genotypic and phenotypic diversity exist within tumors that arise driven by genetic mutations,
epigenetic alterations or microenvironmental influence. As a consequence, expansion of
selected clones as well as establishment of differentiation hierarchies of cancer stem cells
(CSCs) and non-CSCs creates a wide diversity of cells [3]. The basis for the genotypic hetero-
geneity is the inherent genetic instability of cancer cells and the clonal evolution theory that
proposes that a tumor of monoclonal origin may become heterogeneous due to advantageous
tumorigenic growth of clonal subpopulations. Over time, as the tumor progresses, cancer cells
accumulate different mutations and different clones may compete or evolve in parallel gener-
ating a tumor composed of cells with varied genetic imprints. The latter is called branched
evolution, and this process has been confirmed by genetic analysis in a variety of tumors [3].
Non-genetic heterogeneity (phenotypic heterogeneity) is the result of microenvironmental
pressures due to, for instance, alterations in oxygen, pH and nutrient availability based on
their regional location within the primary tumor largely influenced by their relative distance to
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blood vessels. Both genotypic and phenotypic heterogeneity are associated with chemoresist-
ance that have a profound impact on the clinical outcome of lung cancer patients. For instance,
at the clinical level, it has been recently suggested that increased metabolic heterogeneity
should be considered as a high-risk subpopulation for early EGFR TKI failure [4].
1.2. Presence of cancer stem-like cells in lung tumors
The cancer stem cell hypothesis (CSCH) suggests that most cancers contain a rare subpopulation
of cancer cells with properties such as indefinite self-renewal, slow replication and ability to give
rise to differentiated progeny. These cells possess intrinsic resistance to chemotherapy and
radiotherapy and are thought to be responsible for tumor initiation and growth and tumor
relapse [5, 6]. The CSCH is a hierarchical model in which cancer stem cells (CSCs) can differen-
tiate into non-cancer stem cells (non-CSCs) but not the other way around. According to this
model, eliminating the CSC subpopulation would eventually lead to a cure. This concept has
been recently challenged by several alternative models of cancer stem cell biology [7, 8] since
experimental evidence demonstrated that cancer cells are extremely plastic [9, 10] and evidence
of interconversion between CSCs and non-CSCs was found in a variety of cancer types including
lung [11], breast [12] and colon [13] cancers. Contrary to the CSCH, all the alternative models
propose that to cure cancer all cancer cells should be eliminated at once. At present, it is safe to
assume that tumors may consist of a heterogeneous population of cancer cells with different
“stemness” properties ranging from a pure non-CSC phenotype (typically sensitive to conven-
tional anticancer drugs) to a pure CSC phenotype (usually highly resistant to conventional
anticancer drugs). In vitro, CS-LCs are able to grow in the absence of serum as 3D spheres under
anchorage-independent conditions as floating “tumorspheres” (FTs) and it is thought that the
ability to form clonal spheres is a unique characteristic of CSCs [14, 15]. Because of its 3D
architecture, and the notion that FTs consist of mostly CSCs with inherent chemoresistant
properties, they have widely adopted as system models for drug screening (see Section 2.2.2.).
2. In vitro models for anticancer drug screening
Several in vitro models of lung cancer have been widely used for testing new anticancer drugs.
Historically, 2D cultures were introduced first and chemoresistant cells lines were isolated and
widely used to screen for more effective anticancer drugs. However, since 2D cultures typically
consist of a more homogenous population of cells, 2D systems may not be able to account for
intratumoral heterogeneity. As a result that 3D systems would recapitulate more faithfully, the
heterogeneous nature of cancer cells existing in vivo were soon developed. Before describing
these 3D systems, we will briefly discuss 2D systems.
2.1. 2D systems
Some cell lines were found to be inherently resistant to one or more drugs. In addition, several
drug-resistant cancer cell lines have been generated in the laboratory to investigate either the
underlying mechanism of resistance to a particular drug and/or to screen for alternative drug
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able to circumvent the acquired resistant. The next three sections will focus in the development
and characterization of cancer-resistant cell lines and their application to identify mechanism
of resistance and identification of new targets.
2.1.1. Development of drug-resistant cellular models of lung cancer
Developing models of chemoresistant cancer cells is a well-utilized approach to investigate
mechanisms of acquired drug resistance, anticancer drug screening and developing novel drugs
to resensitize resistant cancers to apoptotic stimuli. Developing a stable clinically relevant drug-
resistant model involves using doses and exposure times consistent with the clinical setting [16].
In order to mimic clinical conditions, developing in vitro models of cancer resistance involves
chronic exposure to lower concentration of drug with a pulsed treatment strategy that involves
cycles of exposure to drug followed by recovery in drug-free medium [17]. Alternatively, contin-
uous selection strategy with increasing doses or acute exposure to high concentration of gefitinib
and erlotinib has been used to develop resistant models of NSCLC [18–20].
2.1.2. Characterization of drug-resistant models
Several assays have been used to characterize chemoresistance by comparing the resistant
phenotype with the parental cell line. Measurement of drug sensitivity using viability assays
such as the MTT assay, flow cytometry analysis to determine cell cycle arrest, clonogenic
survival assay, characterization of stemness markers, determination of ALDH activity, expres-
sion of EMT markers, characterization of MDR modulators and quantification of cellular
uptake of drug used to induce drug resistance are commonly used assays to characterize drug
resistance. A dose and time-response curve of cell viability is used to calculate IC50. The fold
resistance is calculated by comparing the ratios of IC50 of the resistant cells with parental cells
[17]. A marked feature of drug-resistant cell lines is enrichment of cancer stem cells, a subpop-
ulation of tumor cells with capacity for self-renewal and tumorigenicity potential. Aldehyde
dehydrogenase (ALDH) is involved in differentiation of cancer stem cells and promoting
resistance and survival mechanisms [21]. Aberration in regular cell cycle can circumvent or
potentiate apoptosis, and drug-resistant cells undergo cell cycle arrest to prevent apoptotic cell
death [22]. Epithelial mesenchymal transition has been associated with resistance to gefitinib
and erlotinib in NSCLC [23, 24]. Quantifying decreased cellular drug accumulation in the
resistant phenotype using inductively coupled plasma mass spectrometry (ICP-MS) due to
overexpression of transporter proteins is another novel method of characterizing acquired
drug resistance [25, 26].
2.1.3. Identifying mechanisms of resistance and novel drug targets for resistant lung cancer
Epidermal growth factor receptor (EGFR), a transmembrane receptor tyrosine kinase (RTK),
involved in cellular proliferation is overexpressed in NSCLC and SCLC. Targeting EGFR signal-
ing using tyrosine kinase inhibitors (TKI) such as gefitinib and erlotinib was a reasonable clinical
success, particularly in patients with EGFR mutations [27, 28]. Acquisition of resistance due to a
secondary mutation of EGFR (T790M) is a major therapeutic problem necessitating discovery of
novel drugs that can inhibit TKI-resistant NSCLC after developing T790Mmutation [29]. A panel
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of 12 NSCLC cell lines comprising wild-type EGFR (TKI-resistant), EGFR mutation with an
additional TKI-resistance inducing mutation and EGFR mutation yet sensitive to TKI-inhibitor
was used to screen 10 anticancer compounds. All 12 NSCLC cell lines showed inhibition of prol-
iferation with 17-DMAG, an Hsp90 inhibitor and belinostat, a histone-deacetylase inhibitor
(HDACi). 17-DMAG and belinostat inhibited EGFR and p-Akt expression in one cell line of each
group. Combination of 17-DMAG and belinostat showed synergistic antiproliferative activity
and inhibited the growth of TKI-resistant cell lines. These drugs were effective in mice xenografts
and completely suppressed tumor growth with the combination being more effective than either
drug alone. Immunoblotting of mice tumors showed decreased expression of p-EGFR, total
EGFR and p-Akt substantiating a need to validate a combination therapy of 17-DMAG and
belinostat in patients with EGFR-TKI-resistant NSCLC [30].
Some mechanisms shown to confer resistance to gefitinib and erlotinib in EGFR-mutated patie-
nts in addition to T790 M mutation, stemness and EMT have been shown to be MET amplifica-
tion, FGFR1 overexpression and IGF1R overexpression [30–32]. These multiple resistance
mechanisms can exist in parallel giving rise to heterogeneous resistant cell population. NSCLC
grown resistant to erlotinib identified subclones that underwent MET amplification or induced
EMT phenotype. MET subclones, while maintaining erlotinib resistance, showed increased sen-
sitivity to MET inhibitors, crizotinib and capmatinib. EMT subclones overexpressed FGFR1 and
showed increased sensitivity to FGFR1 inhibitor AZD4547. Inhibitors of MET and FGFR1
showed reduced sensitivity to mixed NSCLC cell line as compared to the individual subclones.
This study highlights the coexistence of parallel resistance mechanisms giving rise to heteroge-
neous resistant population [33]. Anaplastic lymphoma kinase (ALK) gene rearrangements act as
oncogenic drivers and are present in a small subset of NSCLC, which are responsive to ALK
kinase inhibitors such as ceritinib (LDK378) [34]. Ceritinib-resistant cells were grown by chronic
exposure to the drug and assayed for resistance using cell proliferation and viability assays.
Ceritinib treatment upregulated Src, an oncogene involved in tumorigenesis and metastatic
progression. Knockdown of Src with siRNA in resistant phenotype resensitized cells to ALK
inhibition with ceritinib. Resistant ALK-positive cell lines showed sensitivity to Src inhibitor
ADZ0530, which has promising therapeutic potential to be explored in patients with ALK-TKI-
resistant tumors [35]. In another study, combinatorial treatment of ALK and IGF1R inhibitor was
used to overcome crizotinib resistance in ALK-positive lung cancer, positing IGF1R to be an
independent drug target in this subset of lung cancer [36]. Interleukin-8 is upregulated in
gefitinib-resistant cells and is associated with shorter progression-free survival in EGFR-TKI-
treated lung cancer patients. IL-8 expressing EGFR-mutant cell line showed increased phosphor-
ylation of Akt and NF-κB translocation and decreased sensitivity to gefitinib-induced apoptosis.
Knocking down IL-8 increased the apoptotic sensitivity to gefitinib. IL-8 expressing cells showed
stemness as characterized by ALDH activity, increased expression of Nanog, Oct4 and Sox2 and
forming more and larger colonies than controls. This acquisition of stemness was IL-8 depen-
dent, as knocking down IL-8 reversed the stem cell-like properties in EGFR-TKI- resistant cells
[37]. Gefitinib-resistant cells were developed to investigate the induction of EMT phenotype
associated with EGFR-TKI resistance in NSCLC. While these resistant phenotypes were negative
for T790 M mutation or MET-amplification, they had acquired the EMT phenotype with
increased migratory and invasive phenotype. The acquisition of EMT phenotype was mediated
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via the activation of IGF1R/NF-κB signaling pathway. Inhibition of IGF1R/NF-κB signaling
restored the sensitivity to gefitinib and suppressed the migration and invasion capability,
suggesting that this pathway could be a novel target for gefitinib-resistant EGFR-mutant NSCLC
therapy [38].
To summarize, despite the wide variety of cancer drugs available to treat lung cancer, acquired
resistance to therapy is still a frequently encountered problem. It is important to identify the
resistance conferring mechanisms, so that the resistance can be circumvented or reversed with
novel anticancer drugs. Although drug-resistant cell lines provide robust preclinical models to
interrogate underlying mechanisms of resistance and anticancer drug screening, they lack key
features present in vivo in primary tumors that may provide additional mechanism associated
with chemoresistance.
2.2. 3D systems
Although a plethora of 3D systems have been developed for anticancer drug screening at
present, despite some technical traits, none of these systems showed a clear advantage over
other regarding the ability to select successful clinically useful anticancer drugs. For space
limitations, only floating spheroids and floating tumorspheres will be addressed in this chap-
ter. Figure 1 shows representative microscopy image of spheroids and tumorspheres.
2.2.1. Floating spheroids
The 3D multicellular aggregates formed from single cell suspensions in FBS containing media
under anchorage-dependent or independent conditions are commonly known as “Spheroids.”
It is an excellent 3D model for drug screening as it can closely mimic tumor heterogeneity,
tumor microenvironment niches (normoxic, hypoxic, pH gradient zones) and tumor structural
as well as functional intricacies. Spheroids with constant size and consistent structural features
are necessary to generate consistent and reproducible results.
Researchers have developed various techniques to develop spheroids to achieve these targets. The
commonly used 3D cell culture methods can be divided into two main categories—(i) scaffold
Figure 1. Representative images of H460 lung cancer cells growing as floating spheroids in serum-containing media (A)
or as floating tumorspheres in serum-free media (B). Image in B was reprinted with permission from [39]. Bar = 100 μm.
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based (hydrogel and inserts) and (ii) non-scaffold based. Scaffold-based methods involve colla-
gen-, chitosan- and polycaprolactone-based biomaterials, which serve as extracellular matrix and
provide a 3D architecture for the growth of cells in anchorage-dependent manner in 3D cellular
entities. Non-scaffold-based approaches employ techniques such as forced floating, rotary
devices, hanging drop arrays, microfluidics, etc. to generate spheroids. Forced floating is the
simplest and most commonly used method for the spheroids in a laboratory setting. As the name
suggests, forced floating of cells is achieved by culturing them in vessels that have been coated
with poly-HEMA or agarose suspensions, which prevents attachment of cells to the substratum.
This method has been successfully used to generate spheroids of various types of cancers. It is a
simple, inexpensive and convenient method for generating spheroids; however, it produces
spheroids of variable sizes and shapes. In a recent study, Ivascu et al. reported the use of
centrifugation to generate spheroids of fixed size using forced suspension method [40]. They
added cell suspensions containing a fixed number of cells in each well of poly-HEMA-coated 96-
well plates and subsequently centrifuged the plates to colocalize them. They reported formation
of uniform single spheroids per well as early as 24 hours. Rotary 3D culture techniques work on
agitation principle, which prevents cells from attaching to the container and instead cells interact
with each other and develop 3D spheroids. Rotary culture methods can be sub divided into two
main categories: (i) spinner flask and (ii) rotational culture systems. In spinner flask method, cell
suspensions are constantly agitated by magnetic stirrer, while in rotational culture system cell
suspension media is moved by rotating the culture vessel itself. Both these methods can produce
large amount of spheroids and can be used for long-term production of spheroids. As culture is
constant, agitated cells receive constant supply of nutrients and oxygen. However, size and
structure of the spheroids cannot be controlled in these 3D culture methods. As these methods
rely on constant moving of culture media, it exerts extensive force on cells which can either
damage or affect cellular physiology of the cells. Rotational culture system is a superior technique
than spinner flask method as it exerts far less force on the cells [41]. Kelm et al. developed hanging
drop method for the generation of multicellular spheroids [42]. This method employs gravity as a
force to bring the cells together to generate spheroids. Small aliquots of cell suspension media
(usually 20 μL) carrying fixed number of cells are placed in wells of microtiter plate. These plates
are then inverted and suspension media forms a drop and cells migrate to the tip of the drop due
to gravity. These cells are then allowed to proliferate and generate a single spheroid per well. This
method is good for high throughput, and spheroids with consistent size can be generated with
excellent reproducibility. One limitation of this method is the volume of the liquid (up to 50 μL)
that can be used to generate drop as surface tension can keep only small volumes of media
together. Since small volumes of media are used for drop generation, this method requires
constant media replacement making maintenance of culture challenging [43]. Tan et al. used a
microfluidic platform to generate spheres [44]. This platform consists of a main channel and an
array of coated microwells. Media containing single cell suspension flows through the channel
and the cells get trapped into the wells where they grow in close contact and generate a single
spheroid per well. Size and shape of the spheroids can be controlled by this method. It is a very
good platform for high throughput drug screening and compatible with multidimensional imag-
ing. However, spheroids generated in microfluidic platform cannot be retrieved for further study
and structural analysis. In addition, several coculture methods have been developed to mimic
complex cancer cell and microenvironment interactions. Tumor microenvironment is a complex
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system that involves interactions between tumor cells and adjacent stroma cells (fibroblasts,
endothelial and inflammatory cells) embedded in extracellular matrix (ECM). Spheroids genera-
tion using a coculture model by coculturing cancer cells and fibroblasts and/or immune cells has
been reported and studied for their unique interaction and subsequent effect on carcinogenesis
[45, 46]. Spheroids perfectly mimic an avascular tumor microenvironment and cellular heteroge-
neity. Similar to tumor a nutrient, oxygen and pH gradient exist in spheroids leading to three
distinct cellular zones in the spheroids [47]. The central necrotic zone, whichmostly constituted by
dead cells, is devoid of oxygen and nutrients. This is followed by middle dormant (senescent)
zone consisted of quiescent cells. The peripheral layer, which has sufficient supply of nutrients
and oxygen, has proliferative cells. Microelectrodes and proton magnetic resonance with pH-
sensitive indicators are commonly used techniques to study oxygen flow and pH inside the
spheroids [48, 49]. Figure 2 illustrates the complex 3 architecture of spheroids.
In general, 3D spheroids show less chemosensitivity towards various drugs compared to 2D
in vitro cell culture models [50, 51]. This differential response can be attributed to structural
and functional complexity of 3D model vs. a 2D model. Drug penetration is one of the reasons
of this resistance as the structural and microenvironmental barriers prevent effective convec-
tion of drug in 3D spheroids. As a result, drug fails to achieve an effective concentration inside
the tumor to deliver a strong anticancer response. Kerr et al. demonstrated that reduced
penetration of anthracycline-based drugs was responsible for a mild cytotoxic effect of these
drugs in lung spheroids and a more lipophilic analogue partitioned better hence can be a better
therapeutic option against 3D spheroids [52]. A recent study by Gupta et al. showed improved
efficacy of paclitaxel when coadministered with tumor penetrating peptide iRGD due to
increased availability of the drug in the interior of A549 spheroids [53]. Similarly, tumor
Figure 2. Structural organization of spheroids. (A) Cells are organized in three distinct zones based on viability and
proliferative status of the contributing cells. The innermost necrotic layer is mostly composed of dead cells, which is
followed by middle senescent layer consisting of slowly growing quiescent cells. The outermost layer is proliferative and
contains rapid dividing cells. (B) A gradient of nutrients, oxygen and pH is responsible for this structural organization of
cells in spheroids. Since the interior section of the spheroids receives least amount of nutrients and oxygen, the survival of
cells in this part of the spheroid is compromised. As supply of nutrients and oxygen improve frommoderate to high in the
middle and outer section of spheroids, cells change from quiescent to highly proliferative in these zones.
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heterogeneity arising from the distinct arrangement of cells in different proliferative zones in
spheroids can promote resistance to certain drugs. For example, antiproliferative drugs such as
paclitaxel, which confers most activity towards rapidly dividing cells, showed a reduced
activity towards interior region of spheroid as it consists of quiescent cells [54]. Drugs like
doxorubicin which induce anticancer effect by producing reactive oxygen species show limited
response under hypoxic conditions [55]. However, drugs which get activated under hypoxic
conditions can potentially treat hypoxic tumors. In 2012, Meng et al. observed that a hypoxia-
selective drug TH-302 showed 650-fold greater activity in hypoxic H460 lung cancer cell
spheroids than in monolayer cells [56]. Cancer cells switch their metabolism to glycolysis and
produce lactic acid in the process. A lack of effective clearing of this excess lactic acid results in
accumulation of lactic acid and subsequent reduction of pH in the interior of the tumor. A
reduced pH of the tumor microenvironment can adversely affect the cytotoxicity of weak basic
drugs such as doxorubicin, mitoxantrone, vincristine, etc. These drugs get protonated under
acidic conditions resulting in decreased cellular uptake, hence lose their activity [57]. Activa-
tions of mechanisms related to drug efflux in spheroid can be responsible for increased
resistance to the drugs. In 2015, Rodriguez et al. showed an increased expression of MDR-1
and P-glycoprotein in spheroids of INER-37 human NSCLC cell line compared to 2D culture
likely responsible for increased drug resistance [58]. Several studies have indicated CSC
enrichment in spheroids as possible explanation for drug resistance and metastasis [59, 60]. A
3D spheroid platform is a more relevant model for anti-cancer drug screening, and represents a
much better approach to achieving therapeutic outcomes for cancer patients as compared to
current therapeutic practices. There is need to develop drugs with better penetrating ability to
improve its availability to the most interior sections of tumors. Improved drug delivery tech-
niques employing vehicles, such as nanoparticles, liposomes, nanospheres, etc., can (i) improve
drug delivery and (ii) protect drug decomposition under harsh tumor microenvironment.
Tumor heterogeneity arising from cells of different metabolic, proliferative, chemosensitivity,
metastatic and stemness profile calls for a more complex and versatile therapy approach for
cancer treatment. For example—a cotherapy approach using multiple drugs which can target
different populations of cancer cells will have better outcome for patients than a simple single
therapy approach. Development of better drugs with single drugs targeting multiple pathways
can remove the need to use multiple drugs simultaneously. So, an effective and improved drug
development, drug delivery and drug testing programme are the need of hour to make signif-
icant inroads in a fight against cancer. It is important to mention that Steadman et al. raised
concerns about the possibility that the chemoresistance mechanisms found in spheroids may
differ from the resistance found in intractable solid tumors in patients [61]. If this is the case,
drugs selected by this system will be ineffective in primary tumors. Future studies should be
aimed to attempt to recapitulate in vitro, the complex architecture of lung tumors should take in
consideration several factors known to simultaneously contribute to chemoresistance.
2.2.2. Floating tumorspheres
Cancer is a complex disease with several preventive mechanisms put in place to escape elimina-
tion by immune response, drug efflux or expulsion mechanisms to mitigate drug activity and a
microenvironment uniquely suitable for cancer cells. The matter is further complicated by tumor
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heterogeneity resulting in mixed population of cells with varying degree of chemoresistance,
invasive and migratory potential. Several cancer models have been proposed to explain tumor
heterogeneity and related tumor characteristics. Clonal evolution model (CEM) and cancer stem
cell model (CSCM) are two of the most popular and widely accepted models. CEM postulates
clonal evolution of tumor and suggests existence of several clones with varying genetic and
epigenetic modifications as the contributor for tumor heterogeneity. Lately, CSCM has become
most commonly used model for tumor biology. According to CSCM, a rare but fixed population
of cells known as cancer stem cells (CSCs) with indefinite self-renewal potential and pluripo-
tency are responsible for tumor origin, heterogeneity, metastasis, resistance and relapse. CSCs
are rare cells andmost of the times only constitute 1% of tumor volume. Over the period, various
methods and techniques have been developed to enrich and study the CSC. Fluorescence-
activated cell sorting (FACS) using surface markers, culture of cells in suspension for generating
tumorspheres with increased stemness, sorting of cells based on the activity of intracellular
enzymes such as aldehyde dehydrogenase (ALDH) and 26S proteosome and sorting of side
population cells due to their ability to exclude Hoechst 33342 are some of the most commonly
used methods for CSC sorting and subsequent enrichment. Generation of tumorspheres is most
convenient and cost-effective way for enriching CSCs as it does not require previous knowledge
of surface marker or enzyme expression and costly cell sorting FACS set up. For this chapter, we
will focus on generation of floating tumorspheres and their use as a model for studying chemo-
resistance. In 1996, Reynolds et al. described the generation of normal neural stem cells as
“neurospheres” upon culture of brain cells in floating conditions in serum-free medium suppl-
emented with epidermal growth factor (EGF) and fibroblast growth factor (FGF) [62]. Following
the same culture protocol, Singh et al. generated tumorspheres from the brain tumor cells [63].
Soon after, the method was widely accepted and researcher all over the world used this protocol
to generate tumorspheres from a wide variety of cancers [64–68]. Over the course of time,
researchers have tried to improve upon the existing protocol of sphere formation in order to
make it more efficient, consistent, reliable and physiologically relevant. Various types of scaffolds
consisting of chitosan-alginate, collagen, alginate and agarose have been used as 3D matrices to
substitute low attachment plates [69–72]. In 2014, Cao et al. generated tumorspheres from
primary neuroblastoma cells driven from MYCN transgenic mice using a medium suppleme-
nted with fetal bovine serum (FBS) and β-mercaptoethanol. These spheres exhibited indefinite
renewal as they could be passaged more than 20 times and also demonstrated enhanced meta-
static potential [73]. More recently, in one of our studies, we described culture of lung
tumorspheres (LTs) from H460 cells solely in serum-free media without supplementation of
growth factors [39]. This method was further extended to mammospheres (MSs) generation in
MCF-7 cells [74].
Over a period, several targeted therapies have been developed towards various oncogenic
drivers (EGFR, ALK, ROS1, RET, etc.) in lung cancer [75]. However, most of these drugs have
shown a transient effect on cancer as initial remission of disease is followed by outbreak of more
aggressive and resistant cancer resulting in modest overall survival. Therapy resistance is a
leading hurdle in cancer treatment and mostly responsible for poor outcome for the patients.
Several researchers have identified acquired mutations during the prolonged treatment with a
single drug as the leading cause for the therapy resistance. As discussed in more detail in the
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previous section (Section 2.1.3.), secondary mutations, bypass pathways such as MET, amplifica-
tion of HER2, overexpression of AXL kinase, etc. have been shown to induce therapy resistance
in lung cancer [75–78]. With the advent of concept of CSCs and subsequent discovery of CSCs in
several types of cancers, researchers started to explore a possible link between therapy resistance
and possible changes in the CSCs population. In 2008, Levina et al. were the first researchers to
report the enrichment of cancer stem-like cells (CSLCs) in response to therapy treatment in lung
tumor. They observed that the surviving cancer cell expressed stemness-related markers such as
CD133, CD117, SSEA-3, TRA1-81, Oct4 and nuclear β-catenin. These cells retained a higher
capability to form spheres, self-renewal, differentiation and showed high metastatic and tumor-
igenic potential [79]. Several studies have pointed towards enrichment of CSLCs as a contribut-
ing factor for acquired resistance in lung cancer in response to Cisplatin therapy [25, 80]. Similar
findings have been reported for other commonly used anticancer therapies in lung cancer [81].
Normally, a 2D in vitro model is used for the screening of potential anticancer agents and more
often they fail to translate in vitro antiproliferative efficacy of a drug in in vivo settings. This is due
to an inherently flawed 2D model which does not replicate a real tumor at structural, physico-
chemical, mechanical and biochemical levels. A tumor is a 3D entity composed of cells exhibiting
varying degree of resistance, proliferative andmetastatic tendencies. Tumor microenvironmental
conditions which play a critical role in determining tumor heterogeneity, resistance and metasta-
sis cannot be replicated by an in vitro model, and hence it often fails to impress upon aforemen-
tioned attributes of tumor. Therefore, a more physiologically relevant drug screening tool is a
real necessity to improve upon often failing in vitro cytotoxicity model. Tumorspheres with their
3D structure and often increased stemness can serve as more resistant and invasive model with
closely relatable microenvironmental conditions as that of a real tumor. It can serve as a more
realistic approach for drug screening with better chances of replication of drug efficacy in in vivo
system. Tumorspheres assay can serve as a quick and more economical intermediary testing
platform for in vivo tumor xenograft studies in a high-throughput setting while in vivo studies
can be reserved for validating findings observed in the tumorsphere assays.
In recent years, researchers have successfully employed tumorsphere model for effective
screening of potential anticancer drugs. A number of studies exploring anticancer efficacy of
different classes of compounds such as inorganic [82], natural ingredients [83], antibiotics [84],
Chinese medicine [85], cardiac glycosides [86], etc. against LTs have been published. In vivo
studies have been performed to explore and extend observed drug efficacy against LTs in a
more physiological setting [87, 88]. Several studies have tried combination therapy approaches
in LTs setting to develop effective drug combinations to alleviate therapy resistance-related
concerns and improve efficacy of existing cancer drugs [68, 89–92]. The promising anticancer
drugs selected using tumorspheres described above need to pass the test of more relevant
animal models and later on successful clinical trials to validate the applicability of this 3D
system for anticancer drug screening.
2.2.3. 3D systems as models to test drug delivery and efficacy
Drug delivery refers to approaches, formulations, technologies and systems for transporting and
administering in vivo an active pharmaceutical ingredient (API) to achieve a therapeutic effect in
Chemoresistance of Lung Cancer Cells: 2D and 3D In Vitro Models for Anticancer Drug Screening
http://dx.doi.org/10.5772/intechopen.78946
183
the patient. In tumors, there are gradients of drug concentrations, oxygen and nutrients created
by the distance from blood vessels. These similarities make 3D systems the more physiological
models for drug delivery testing and therefore better predictors of chemosensitivity. Metha et al.
[93] described in detail six characteristics of spheroids, which are absent in conventional culture
formats, that mimic how drug delivery might occur in vivo: (1) spheroids model the 3D architec-
ture of tissues, including multicellular arrangement and extracellular matrix deposition, found
in vivo. (2) Spheroids have sizeable cell-cell interactions, including tight junctions that are known
to influence response of cells to drugs, (3) spheroids have diffusional limits to mass transport of
drugs, nutrients and other factors, (4) spheroids are formed with two or more cell types in
varying ratios representing intercellular signaling and architecture that can help to understand
how multiple cell types might impact drug delivery, (5) rare cells such as cancer stem cells or
primary stem cells may be present or incorporated and maintained in spheroids which can
facilitate targeting these specific cells with drugs and (6) larger spheroids develop central necro-
sis and regions of hypoxia present in many cancers. These specific microenvironments have been
shown to contain cancer cells with increased chemoresistance. Tumorspheres share most of these
characteristics with few differences: (1) they are considered to be enriched with CS-LCs that are
inherently more resistant than non-CS-LCs and (2) tumorspheres can be generated in complete
absence of external mitogenic stimulation that makes ideal system to study how specific factors
(sometimes present in serum-containing media) may alter the response of cancer cells to antican-
cer drugs. For instance, lung tumorspheres grown in the absence of external mitogenic stimuli
when exposed to exogenously added EGF demonstrated increased sensitivity to Erlotinib and
Gefitinib [10]. In summary, despite their limitations, both spheroids and tumorspheres are useful
and complementary systems for drug delivery testing.
3. Implications for translational oncology
The in vitro identification of effective anticancer is a crucial part of the anticancer drug screening
program. Drug development is a long and expensive business, and billions of dollars are
invested for a single successful drug release in market. It starts at identification of potential drug
candidate with subsequent testing in vitro and in vivo setting followed by testing in various
phases of clinical trials. Upon successful completion of clinical trial, drug is approved by FDA
for marketing. Therefore, development of realistic models of drug screening is extremely impor-
tant for vetting of drug candidates in earlier preclinical stages for them to have better chances to
be successful in later clinical trials. Traditionally, 2D in vitro culture model is used for cancer drug
screening. However, it completely fails to recapture finer intricacies of 3D tumor. It does not have
any semblance with a 3D tumor at microenvironmental, biological and physiological levels and
hence in most instances miserably fails in therapy translation from an in vitro to an in vivo setting.
In order to address these issues, researchers have developed various drug screening 3D models,
which align well, mimic essence of natural tumors and carry more significance as drug screening
platforms. Despite these important technical advances, few drugs have been translated into
clinical practice and the prognosis of lung cancer patients remains poor, suggesting that current
in vitro 3D models are still not good models of primary tumors.
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4. Conclusions
At present, current in vitro 3D models offer significant advantages over 2D systems in terms of
recapitulating intratumoral heterogeneity and enrichment of cancer stem cells and have been
extremely useful for understanding cancer cell biology. However, for anticancer drugs discovery,
this success has not been translated into the clinic because the prognosis of lung cancer patients
still remains poor. Future development in the field should concentrate on (i) efforts to better
mimic in vivo conditions and (ii) identifying the underlying mechanism of chemoresistance of
in vitro system in correlation with in vivo conditions. Otherwise, drugs selected with the current
method will only target a subpopulation of chemoresistant cells or as suggested by Steadman
et al. will be ineffective due to differences in the underlying mechanism of chemoresistance
between in vitro 3D system and in vivo conditions.
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